Conversations about Mounjaro and Ozempic are, at this point, almost unavoidable. Most visits now include some version of the same question — is this something I should be on, and if so, is one better than the other? The honest answer involves more than the headline weight-loss number you’ve seen in the news. Below is the fuller picture: what the trials actually show, how these drugs are dosed and tolerated, what happens when you stop, who should think twice, and what they really cost in 2026.
What Is a GLP-1?
Before we get into choosing a GLP-1 medication, let’s talk about what this medication actually is. GLP-1 stands for glucagon-like peptide-1, a hormone naturally produced by the body that helps regulate appetite, digestion, and blood sugar. GLP-1 medications mimic the effects of the body’s natural GLP-1, helping improve blood sugar control and, for some people, making them an effective treatment for weight loss. Depending on the medication, GLP-1 therapy may be used to manage type 2 diabetes or support weight management, alongside diet and exercise. Several medications like semaglutide and tirzepatide have been approved by the FDA for specific uses. Like any medication, taking a GLP-1 can cause common side effects, including nausea, vomiting, diarrhea, and other digestive symptoms, so it’s important to discuss these with your provider to determine whether it fits into your individual treatment plan.
There are several GLP-1 options available, with differences in how they work, how they are taken, and what they are approved to treat. In the sections below, we’ll take a closer look at the most common options and what to consider when choosing the right one for you.
How GLP-1 Actually Works: The Multi-Organ Effect
These drugs do more than lower blood sugar because GLP-1 receptors sit throughout the body, not just the pancreas — touching appetite, the heart, liver, kidneys, and possibly the brain, all at once.
The pancreas — insulin, but smarter
GLP-1 stimulates insulin only when blood sugar is elevated — why these drugs rarely cause low-blood-sugar crashes. It also suppresses glucagon, the hormone that tells the liver to release more sugar, and may help insulin-producing cells survive and regenerate — a potentially disease-modifying effect in type 2 diabetes, not just symptom management.
The brain — where the weight loss actually happens
This is what surprises most patients: appetite suppression isn’t just willpower assisted by nausea. GLP-1 acts on the hypothalamus to increase satiety and on the brain’s reward circuitry, cutting cravings for high-fat, high-sugar foods and blunting the pleasure of eating them, while also signaling fullness independent of stomach stretch. This central effect, not eating less, drives the weight loss — patients often describe wanting less food, not just smaller portions.
The stomach — where the side effects come from
Slower gastric emptying does double duty — it’s why you feel full longer after meals and blood sugar spikes are blunted, but it’s also the mechanical source of the nausea and vomiting behind most early discontinuations. Same mechanism, benefit and downside.
The heart and blood vessels
This is the direct cardioprotective effect behind the SELECT findings — calming vessel-wall inflammation, improving endothelial function, and modestly lowering blood pressure, independent of glucose or weight. It isn’t just semaglutide: LEADER, SUSTAIN-6, and REWIND all showed similar reductions in heart attack, stroke, and cardiovascular death in diabetics, well before SELECT extended the finding to non-diabetics.
The liver
GLP-1 reduces fat accumulation in the liver directly, and — per the ESSENCE data above — there’s now real trial evidence of benefit in MASLD/MASH, not just theory.
The kidneys
Beyond FLOW’s headline numbers, the mechanism looks like reduced albuminuria, slower progression of diabetic kidney disease, and less kidney inflammation.
The brain, again — the neuroprotection question
This is the newest piece, and where the story got complicated. There’s real evidence GLP-1 reduces neuroinflammation, and observational data link its use to lower Alzheimer’s and dementia risk. But tested directly, in two large randomized trials of semaglutide for early Alzheimer’s disease (EVOKE and EVOKE+), it didn’t outperform placebo on the primary cognitive measure. It did reduce several Alzheimer’s biomarkers, just not enough for measurable benefit, and the trials’ extension phase has since been discontinued — a reminder that promising observational signals don’t always survive a randomized trial.
Weight Loss With a GLP-1: The Real Numbers
We finally have a real head-to-head answer. The SURMOUNT-5 trial (Aronne et al., NEJM, May 2025) put both drugs to the test directly — 751 adults with obesity, no diabetes, each titrated to the maximum tolerated dose over 72 weeks. Tirzepatide won out, producing 20.2% average weight loss compared with 13.7% for semaglutide, along with bigger improvements in waist circumference, blood pressure, blood sugar, and cholesterol. Both drugs level off somewhere around 15 to 18 months of use — this isn’t a medication that keeps working at the same pace forever.
What titration actually looks like
Neither drug starts you at the dose that actually works. Both are titrated up slowly on purpose, to blunt the Gastrointestinal side effects, and rushing that process is the single most common reason I see patients quit early.
Don’t expect much movement on the scale in the first month — meaningful weight loss usually kicks in around weeks 8 to 12, once you’ve reached a dose that’s actually doing something. The nausea and GI upset tend to be worst right after each dose increase and settle down within a week or two. If they don’t settle, we can simply hold you at that dose a little longer before stepping up — most patients don’t realize that’s an option, and it beats quitting altogether.
Starting GLP-1 Therapy: What I Tell Patients
Before we even write the prescription, I want you already moving in the right direction. Patients who build up some resistance training and raise their protein intake two to three weeks before their first dose tend to hold onto more muscle throughout the entire course of treatment, not just at the end. This doesn’t mean joining a gym — two short sessions a week of bodyweight exercise or resistance bands is a real starting point, and it’s far easier to build that habit before your appetite changes than after. The same protein target that matters later matters just as much now: roughly 0.6 to 0.7 grams per pound of body weight a day, or about 100 grams for a 160-pound patient. Getting into that rhythm before you start means you’re protecting muscle from day one, instead of trying to catch up once the weight is already coming off.
- Eat slowly and stop before you feel full — your old cues for “full” arrive late now.
- Fatty, greasy, or oversized meals trigger nausea more than total calories do, especially early on.
- Constipation is common and easy to under-treat. Start fiber, water, and a stool softener from day one.
- Alcohol tends to hit harder and faster once you’re on these drugs.
- Keep a running list of side effects and bring it to your visit — most tolerability problems get fixed by slowing the titration, not by stopping the drug altogether.
The Heart Benefit Isn’t Just About The Scale
The SELECT trial (Lincoff et al., NEJM, December 2023) is the one that changed how I think about these drugs. It followed 17,604 patients across 41 countries — mean age 61.6, more than a third already over 65 — all with established heart disease and a BMI of 27 or higher, and notably, none of them diabetic. Semaglutide cut the combined risk of cardiovascular death, heart attack, or stroke by 20% over about three and a half years, and along the way it also cut progression to diabetes by 73% and reduced major kidney complications by roughly 22%.
Here’s the part I found surprising: a follow-up analysis of that same trial, published in The Lancet, found that most of the heart benefit had little to do with weight loss itself. How much weight someone lost early on didn’t predict who’d go on to have fewer heart attacks or strokes, and waist circumference reduction explained only about a third of the overall benefit. The rest seems to come from the drug acting directly on the blood vessels — calming inflammation, improving how the vessel lining functions, and reducing stiffness and scarring in the heart muscle. This looks like a real cardioprotective effect of the drug itself, not simply “lose weight, help your heart.” And important to note, it held up equally well in men and women.
Beyond Weight and Heart: The Data Behind the Headlines
Kidney disease — the FLOW trial (NEJM, 2024)
In 3,533 adults with type 2 diabetes and chronic kidney disease, semaglutide cut major kidney outcomes — kidney failure, a significant drop in kidney function, or death from kidney or heart causes — by 24%, along with an 18% reduction in cardiovascular events and a 20% drop in overall mortality. The benefit was clear enough that researchers stopped the trial early. Like SELECT, this one looks weight-independent too — a mediation analysis found weight loss explained almost none of the kidney benefit, pointing to a direct effect on the kidney itself.
Obstructive sleep apnea — SURMOUNT-OSA (NEJM, 2024)
Tirzepatide cut the number of breathing disruptions per hour of sleep roughly in half compared with placebo, and at the highest dose, 43% to 51.5% of patients met formal criteria for disease resolution within a year. This led to the first FDA approval of a GLP-1/GIP drug specifically for sleep apnea — so if you’ve never been able to tolerate CPAP, this is now a genuine second option worth asking about. Unlike the kidney and heart findings, this one does track closely with how much weight is lost — makes sense, since OSA in obesity is largely a mechanical problem caused by fat around the airway.
Liver disease — the ESSENCE trial (NEJM, 2025)
In adults with MASH (what used to be called NASH) and moderate-to-advanced liver scarring, semaglutide resolved the underlying inflammation without worsening the scarring in 62.9% of patients, compared with 34.3% on placebo, after 72 weeks — with a clean safety profile for the liver. That led to an accelerated FDA approval in August 2025, a genuinely new use for this drug well outside the heart-and-metabolism space. The picture here is mixed: weight loss accounted for most (about 69%) of the steatohepatitis-resolution benefit, but fibrosis improvement specifically was mostly independent of weight loss — a more direct anti-fibrotic effect.
Dementia and cognition — promising data, disappointing trial
This is the most-watched, and now most humbling, data in the whole GLP-1 story. The observational numbers looked terrific: one large study found a 70% lower risk of Alzheimer’s disease in diabetics taking semaglutide compared with insulin, and a meta-analysis pooling more than 160,000 patients found a 45% reduction in Alzheimer’s and dementia risk overall. But observational data can only ever suggest an effect, not prove one. When semaglutide was tested directly against placebo in two large randomized trials of early Alzheimer’s disease (EVOKE and EVOKE+), it didn’t meet the primary endpoint — patients on semaglutide didn’t show meaningfully better cognitive or functional outcomes than those on placebo. The drug did significantly reduce several Alzheimer’s-related biomarkers, just not by enough to produce a measurable clinical benefit, and the manufacturer has since discontinued the trials’ extension phase. For now, I’d call this an open question rather than a promising one: the biological rationale is real, but the best evidence we have says semaglutide alone isn’t an Alzheimer’s treatment. Nobody should start this drug for that reason.
Stopping the Medication: What Aactually Happens When You Stop Taking a GLP-1
This is the conversation patients are least prepared for. In the STEP 1 extension trial, people who’d lost 17.3% of their body weight on semaglutide regained about two-thirds of it within a year of stopping. A separate trial of tirzepatide found much the same thing: 82% of patients who’d lost at least 10% of their body weight regained more than a quarter of it within a year off the drug. Regaining some weight after stopping is closer to the rule than the exception. The genuinely good news is that the regain tends to level off below where you started, not above it — the benefit isn’t completely erased, even if it fades.
Not surprising were the results from the SURMOUNT-MAINTAIN trial: patients who continued on their full dose, or even stepped down to a lower maintenance dose, kept significantly more weight off than those who switched to placebo. I’ve started framing this the same way I frame blood pressure medication — an ongoing, lower-dose maintenance strategy, not a finite course with a built-in stop date.
If you are tapering off, the single best thing you can do is get ahead of it with resistance training and protein — started now, not after the regain has already begun. If you’re not lifting yet, this is the moment to add two to three resistance sessions a week; bodyweight exercises or resistance bands are a fine place to start. Protein is the other lever, and it’s worth having an actual number in mind: aim for roughly 0.6 to 0.7 grams per pound of body weight per day. For a 160-pound patient, that’s about 100 grams a day — roughly a palm-sized portion of chicken, fish, eggs, Greek yogurt, or a protein shake at each of three meals. Doing this while you’re still losing weight protects the muscle you have; trying to rebuild it after regain has already started is a much harder task. Pairing any taper with this kind of structured exercise and behavioral support meaningfully blunts how much weight comes back.
Reasons to Think Twice Before Taking GLP-1
Cost aside, I do want to flag caution for specific patients. If you’re over 60 or 65, you’re already losing some muscle and bone simply with age, and rapid weight loss can compound both — a surprising 25% to 40% of the weight lost on these drugs is lean mass, not fat. That’s exactly why I push resistance training and adequate protein from day one, and why I’ve started checking baseline strength and function before starting anyone past 65.
Absolute and relative contraindications
- Personal or family history of medullary thyroid carcinoma or MEN2 syndrome — absolute contraindication.
- History of pancreatitis — relative contraindication, worth a real discussion.
- Severe gastroparesis — not recommended; the drug’s mechanism will make it worse.
- Active gallbladder disease — can be aggravated by rapid weight loss.
- Pregnancy or trying to conceive — contraindicated.
- Diabetic retinopathy — rapid glucose improvement can transiently worsen it; loop in ophthalmology before aggressive titration.
One practical thing that catches people off guard: because these drugs slow down how quickly your stomach empties, current anesthesia guidelines say we need to hold them before any procedure involving sedation or general anesthesia — usually about a week for the weekly formulations — to lower the risk of aspiration. If you have a colonoscopy, surgery, or any procedure coming up, tell us well ahead of time so we can plan around it.
If you’re a postmenopausal woman, there’s one more thing worth knowing: the bone loss that comes with menopause, combined with drug-induced weight loss, may raise fracture risk more than it does in men. The research here is still catching up, but if you have other risk factors for osteoporosis, a baseline bone density scan (DEXA) is worth considering.
Men, Women, an Age: Who Responds Differently
Women tend to lose more weight on these drugs than men do — about 11% of starting body weight compared with 7% — and that gap widens the more weight someone loses. The cardiovascular benefit doesn’t show that same gap: SELECT’s own subgroup analysis found consistent protection against heart attack and stroke, and consistent diabetes prevention, in both sexes, with slightly better kidney-function preservation in women.
Age turns out to matter less than you’d think for the cardiovascular benefit — more than a third of the SELECT population was already over 65, and the benefit held up consistently across age groups. Where age matters more is body composition: the muscle and bone concerns above get sharper the older you are, and if you only have 15 to 20 pounds to lose, a bigger share of that weight loss comes from muscle, simply because there’s less fat available to draw from first.
The Cost Conversation: Choosing the Right GLP-1 Medication For You
This comes up in nearly every visit, so let’s talk real numbers. Without insurance, list price runs $950 to $1,000 a month for Ozempic, $1,300 to $1,400 for Wegovy, $1,000 to $1,100 for Mounjaro, and $1,050 to $1,150 for Zepbound.
Medicare Part D covers Ozempic and Mounjaro when they’re prescribed for type 2 diabetes, usually for $0 to $50 a month, but it still doesn’t cover Wegovy or Zepbound for weight loss alone. Commercial insurance coverage has gotten better over the past year, though most plans still want prior authorization and documented proof of a BMI of 30 or higher (or 27-plus with a qualifying condition).
LillyDirect, specifically
Most of my cash-pay patients don’t know about this option. Mounjaro through LillyDirect runs a flat $499 a month at any dose — about 54% off list price. Zepbound is priced by dose: $299 at 2.5 mg, $399 at 5 mg, and $449 at 7.5 mg and above, though that top rate only holds if you reorder within 45 days of your last fill — miss it, and you’re back to $599–$1,049. Neither program combines with insurance, Medicare, or Medicaid; it’s cash-pay only. Lilly’s separate charity program, the Lilly Cares Foundation, provides Mounjaro free to uninsured patients at or below 400% of the federal poverty level — there’s no equivalent yet for Zepbound.
If you have commercial insurance, ask about the manufacturer savings card before paying out of pocket — it can bring your copay down to as low as $25 a month if your plan covers the drug, or cap you at $499 a month if it doesn’t. Have the pharmacist run your insurance first and apply the savings card second; the order matters. NovoCare offers something similar for Ozempic and Wegovy, around $349 a month. Ask us about these programs at every renewal, since they tend to change.
What’s Next: The Following Generation
Orforglipron is worth knowing about — it’s the first oral, small-molecule GLP-1 drug, a pill instead of a weekly injection. Phase 3 obesity data (NEJM, September 2025) showed up to 11.2% weight loss at the highest dose, and a companion trial in type 2 diabetes (ATTAIN-2, Lancet) showed similar results. If it holds up, having an oral option could be a real game-changer for patients who are needle-averse, or anywhere refrigerated injectable supply is hard to come by.
Retatrutide, a triple agonist that acts on GIP, GLP-1, and glucagon receptors, has posted the largest weight-loss numbers of any agent tested so far — 11% to 24% depending on dose. Its diabetes data (TRANSCEND-T2D-1, Lancet, 2026) showed HbA1c drops of 1.7% to 1.9%, compared with 0.8% for placebo. It’s still working through its full safety and outcomes program, so consider it one to watch, not one to ask for yet.
The Bottom Line: Choosing a GLP-1 Treatment
These have stopped being just weight-loss drugs. The evidence now reaches the heart, kidneys, liver, and sleep apnea, with a genuinely promising, if not yet proven, signal for the brain too. They’re not without real tradeoffs, though — GI side effects are common, protecting your muscle and bone takes deliberate effort, insurance coverage is still inconsistent, and stopping usually means gaining back much of what you lost. The patients who benefit most tend to share a profile: real cardiometabolic risk to begin with, not just a few pounds to lose, and a willingness to treat this as a years-long commitment rather than a single prescription. In my experience, the ones who do best pair it with strength training, enough protein, a realistic plan for the cost, and a real plan for what happens if they ever taper off — rather than treating it as a quick fix. And because this field is moving faster than almost anything else in medicine right now, what’s true today may look different in a year, which is exactly why this is worth revisiting at every visit rather than deciding once and moving on.
As always, come talk to us before starting or stopping any of these medications. The right choice depends on your cardiovascular risk, kidney function, weight history, and goals.
SELECTED REFERENCES
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. 2023;389:2221-2232. doi:10.1056/NEJMoa2307563
- Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial. Lancet. 2025. doi:10.1016/S0140-6736(25)01375-3
- Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT): Outcomes by Sex. J Am Coll Cardiol. 2024. doi:10.1016/j.jacc.2024.08.022
- Aronne LJ, Horn DB, le Roux CW, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5). N Engl J Med. 2025. doi:10.1056/NEJMoa2416394
- Perkovic V, Tuttle KR, Rossing P, et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW). N Engl J Med. 2024;391:109-121. doi:10.1056/NEJMoa2403347
- Malhotra A, Grunstein RR, Fietze I, et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity (SURMOUNT-OSA). N Engl J Med. 2024;391:1193-1205. doi:10.1056/NEJMoa2404881
- Kosiborod MN, Abildstrøm SZ, Borlaug BA, et al. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity (STEP-HFpEF). N Engl J Med. 2023;389:1069-1084. doi:10.1056/NEJMoa2306963
- Sanyal AJ, Newsome PN, Kliers I, et al. Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis (ESSENCE). N Engl J Med. 2025. doi:10.1056/NEJMoa2413258
- Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553-1564. doi:10.1111/dom.14725
- Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024;331(1):38-48.
Dr. Weiss, MD, August, 2026
Read Also: Encourage Your Valentine To Focus On Their Heart Health This American Heart Month
If you’re in the Bay Area and wondering whether a GLP-1 medication could be right for you, The Village Doctor can help you understand your options and develop a treatment plan tailored to your needs. Contact The Village Doctor today at (650) 851-4747 or Contact us to schedule a consultation and discuss whether GLP-1 therapy is a good fit for your health goals.
